Bladder cancer – progress in the treatment of non‑invasive stages
MUDr. Jana Katolická, Ph.D.
Onkologicko-chirurgické oddělení LF MU a FN u sv. Anny, Brno
Non-invasive urothelial carcinoma of the bladder is commonly treated with topical therapy. Intravesical administration of the BCG vaccine has shown significant benefit in medium and high-risk patients. A new treatment option for non-BCG-responsive tumors is pembrolizumab.
non-invasive urothelial carcinoma of the bladder, BCG vaccine, pembrolizumab
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...